Orlistat Overcoming Third-generation EGFR-TKI Resistance
NCT06818955
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
36
Enrollment
OTHER
Sponsor class
Conditions
Lung Adenocarcinoma
Osimertinib
Interventions
DRUG:
Orlistat 120 mg
Sponsor
Ping Peng
Collaborators
[object Object]